Last June 10, 2025, Culion Foundation, Inc. (CFI), in collaboration with Ritemed and the QCHD – National Tuberculosis Program, launched a new initiative to strengthen TB detection by introducing the Interferon Gamma Release Assay (IGRA) as another form of TB testing under its Active Case Finding (ACF) activities.
IGRA is used to detect latent TB infection (LTBI), particularly among household contacts, and can help determine eligibility for TB Preventive Treatment (TPT).
The CFI TB ACF NCR team, along with Ritemed staff, demonstrated the IGRA procedure step-by-step, highlighting its potential to enhance community-based TB prevention.
